丙型肝炎病毒清除后纤维化逆转:从基础到临床
综述总结丙型肝炎病毒(HCV)清除后肝纤维化与肝硬化可逆性的证据及其对临床结局的影响。直接抗病毒药物(DAA)使广泛患者获得持续病毒学应答(SVR),但纤维化逆转的人群、速度及持续肝硬化者是否需抗纤维化治疗尚不明确,本文探讨相关治疗前景。
要点
- HCV清除后肝纤维化可逆转,但逆转人群与速度尚不明确
- DAA使包括晚期纤维化、肝硬化及并发症患者获得高SVR
- 持续肝硬化者是否需直接抗纤维化治疗仍待明确
核心结论
- HCV清除后肝纤维化和肝硬化可以逆转,但逆转的个体差异、时间进程及持续肝硬化者的抗纤维化治疗指征尚不明确。
研究设计与样本
- 本文为综述,总结HCV eradication后纤维化与肝硬化可逆性、临床结局影响及直接促进纤维化逆转的治疗前景的证据。
主要发现
- 干扰素时代治疗成功率中等且耐受性差,直接抗病毒药物(DAA)使包括晚期纤维化、肝硬化、合并症及肝硬化并发症患者广泛获得持续病毒学应答(SVR)。
- 纤维化是细胞外基质沉积与降解并存的动态过程,多种肝病包括HCV的纤维化可逆转。
- HCV清除后纤维化逆转的人群、速度及持续肝硬化者是否需要抗纤维化治疗尚不确定。
临床怎么用
- 对HCV感染者应使用DAA实现SVR以消除病毒,从而为纤维化逆转创造条件。
- 对已获SVR但纤维化持续存在的患者,需关注纤维化逆转评估及潜在抗纤维化治疗需求。
局限性
- HCV清除后纤维化逆转的人群、速度及持续肝硬化者抗纤维化治疗指征尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatitis C virus (HCV) infection and its complications have been the major cause of cirrhosis and its complications for several decades in the Western world. Until recently, treatment for HCV with interferon-based regimens was associated with moderate success but was difficult to tolerate. More recently, however, an arsenal of novel and highly effective direct-acting antiviral (DAA) drugs has transformed the landscape by curing HCV in a broad range of patients, including those with established advanced fibrosis, cirrhosis, comorbidities, and even those with complications of cirrhosis. Fibrosis is a dynamic process comprising both extracellular matrix deposition, as well as its degradation. With almost universal sustained virologic response (SVR) (ie, elimination of HCV), it is timely to explore whether HCV eradication can reverse fibrosis and cirrhosis. Indeed, fibrosis in several types of liver disease is reversible, including HCV. However, we do not know with certainty in whom fibrosis regression can be expected after HCV elimination, how quickly it occurs, and whether antifibrotic therapies will be indicated in those with persistent cirrhosis. This review summarizes the evidence for reversibility of fibrosis and cirrhosis after HCV eradication, its impact on clinical outcomes, and therapeutic prospects for directly promoting fibrosis regression in patients whose fibrosis persists after SVR.
引用
- Rockey DC, Friedman SL. Fibrosis Regression After Eradication of Hepatitis C Virus: From Bench to Bedside. Gastroenterology. 2021. PMID: 33529675. doi:10.1053/j.gastro.2020.09.065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。